Stay updated with breaking news from Biotech chairman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bharat Biotech International Ltd on Friday said its COVID-19 vaccine Covaxin has proven to be safe, well-tolerated and highly immunogenic in children and adolescents of 2-18 years age group in phase II/III study. ....
CEPI will fund the initiative under its USD 200 million programme to advance the development of vaccines that provide broad protection against SARS-Cov-2 variants and other betacoronaviruses. ....
CEPI on Tuesday said it will provide up to USD 19.3 million (about Rs 149 crore) to Bharat Biotech International, the University of Sydney, and Switzerland-based ExcellGene SA for the development of a "variant-proof" SARS-CoV-2 vaccine candidate. ....
Covaxin ( BBV152) booster, India s indigenous vaccine, has shown that it can neutralize both Omicron and Delta variants of SARS-CoV-2, jab maker Bharat Biotech informed on Wednesday. ....